Overview

Diltiazem in Jervell and Lange-Nielsen Syndrome

Status:
COMPLETED

Trial end date:
2024-10-23

Target enrollment:

Participant gender:

Summary

This study will test the effect of diltiazem, a calcium channel blocking drug, on the QT interval in patients with Jervell and Lange-Nielsen syndrome. This will be a single IV dose and acute effects (within minutes) will be observed.

Phase:

PHASE4

Details

Lead Sponsor:

Vanderbilt University Medical Center

Treatments:

Diltiazem